Outlook Therapeutics, Inc. (OTLK) Revenue History
Annual and quarterly revenue from 2014 to present
OTLK Revenue Over Time (2014–2025)
OTLK Revenue Growth History
2 of 6 years with positive growth- FY2014 revenue growth
- N/A
- FY2015 revenue growth
- -42.3%
- FY2016 revenue growth
- -42.9%
- FY2017 revenue growth
- +27.9%
- FY2018 revenue growth
- -19.0%
- FY2019 revenue growth
- +163.8%
- FY2020 revenue growth
- -100.0%
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $9K | -99.4% |
| Q2 2026 | $127K | — |
| Q1 2026 | $-1,207,833 | — |
| Q4 2025 | $-91,787 | -154.0% |
| Q3 2025 | $1.5M | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $0 | — |
| Q4 2024 | $170K | — |
Multi-year avg. share of annual revenue by fiscal quarter
OTLK Revenue Analysis (2014–2025)
Current Revenue & Growth
As of September 9, 2026, Outlook Therapeutics, Inc. (OTLK) generated trailing twelve-month (TTM) revenue of $-1,163,181, reflecting significant decline in growth of -99.4% year-over-year. The most recent quarter (Q3 2026) recorded $9,000 in revenue, down 92.9% sequentially.
Historical Growth Trajectory
OTLK's historical revenue data shows various trends over time. Outlook Therapeutics, Inc.'s highest annual revenue of $9.1 million was recorded in 2014.
Peer Comparison
Compared to Healthcare sector peers — including ADVM (-100.0% YoY), and REGN (+9.3% YoY) — OTLK has underperformed the peer group in revenue growth. Compare OTLK vs ADVM →
OTLK Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| OTLKCurrent | $-1,163,181 | -99.4% | - | -4744.3% | |
 ADVM | $1M | -100.0% | +32.0% | -13915.9% | |
 REGN | $14.3B | +9.3% | +11.0% | 24.9% |
OTLK Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $1.4M | - | $657K | 46.5% | $-67,061,666 | -4744.3% |
| 2024 | $0 | - | $-113,859 | - | $-71,703,000 | - |
| 2023 | $0 | - | $-44,188 | - | $-53,126,000 | - |
| 2022 | $0 | - | $-204,694 | - | $-63,071,000 | - |
| 2021 | $0 | - | $-262,139 | - | $-51,727,000 | - |
| 2020 | $0 | -100.0% | $-554,069 | - | $-36,841,000 | - |
| 2019 | $8.1M | +163.8% | $-15,659,000 | -192.2% | $-36,299,000 | -445.6% |
| 2018 | $3.1M | -19.0% | $0 | - | $-29,644,000 | -960.0% |
| 2017 | $3.8M | +27.9% | $0 | - | $-35,880,000 | -941.2% |
| 2016 | $3.0M | -42.9% | $0 | - | $-51,347,000 | -1723.1% |
| 2015 | $5.2M | -42.3% | $0 | - | $-46,563,000 | -892.2% |
| 2014 | $9.1M | - | $0 | - | $-12,392,000 | -136.9% |
OTLK Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
12+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
OTLK — Frequently Asked Questions
Quick answers to the most common questions about buying OTLK stock.
Is OTLK's revenue growth accelerating or slowing?
OTLK revenue is declining -99.4% year-over-year. TTM revenue fell to $-1M, contrasting with the 5-year CAGR of N/A. The reversal reflects either macro headwinds or company-specific challenges.
What is OTLK's revenue history from 2014 to 2026?
Outlook Therapeutics, Inc. (OTLK) revenue history spans 2014 to 2026. TTM revenue as of 2026 is $-1M, growing at -99.4% YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is OTLK's long-term revenue growth rate (CAGR)?
Outlook Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -99.4% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for OTLK.
Why does OTLK's quarterly revenue fluctuate?
OTLK quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Outlook Therapeutics, Inc.'s revenue data from 2014 to 2026 shows full historical quarterly detail on this page.
How is OTLK's revenue distributed by segment?
OTLK reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does OTLK's revenue compare to industry peers?
Outlook Therapeutics, Inc. (OTLK) with TTM revenue of $-1M and -99.4% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.